Dogwood Therapeutics, Inc.
DWTXNext catalyst
Halneuron
Chemotherapy Induced Neuropathic Pain
Get an email about DWTX's next catalysts
Track Dogwood Therapeutics (DWTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 3 past
Halneuron Phase 2 Est. Readout
Estimated primary completion for Halneuron trial (NCT06848348) in Chemotherapy Induced Neuropathic Pain. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Halneuron | Phase 2 | Chemotherapy Induced Neuropathic Pain | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Dogwood Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Dogwood Therapeutics, Inc.'s (DWTX) pipeline across Phase 2. Its lead program is Halneuron (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Dogwood Therapeutics, Inc.'s next FDA catalyst?→
Dogwood Therapeutics, Inc.'s (DWTX) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DWTX biotech catalysts?→
Add DWTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Dogwood Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.